The industry needs to tread carefully in the future – but there could be upsides to having less red tape and softer tax policies - Magazine Article - PharmaTimes
by Ana Nicholls
www.pharmatimes.com/magazine/2016/december/trump_and_brexit_good_news_for_pharmaOff-label use of medicines has always been a vexed issue. In theory, treatments should only be used as indicated, where their safety and efficacy has been proven. Indeed, several pharma companies have received large fines for suggesting otherwise in
by Ana Nicholls, Economist Intelligence Unit
www.pharmatimes.com/news/smartviews_off-label_but_under_debate_971338When the media writes about pharma companies’ profitability, it is usually as an accusation. In most industries the ability to stay out of the red would prompt admiration, but there is widespread distaste about profit-making anywhere in the
by Ana Nicholls, Economist Intelligence Unit
www.pharmatimes.com/news/smartviews_pharma_companies_profitability_-_an_accusation_971475With predictions of an additional £10bn hole in NHS finances and recession before 2020, the UK government should reassure pharma that a post-Brexit Britain is worth investing in - Magazine Article - PharmaTimes
by Ana Nicholls
www.pharmatimes.com/magazine/2016/july_2016/smartviews_brexit_-_whats_next_for_pharma
